BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

類似資料

• Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
  著者:: Yang, Renchi, 等
  出版事項: (2019)
• BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review
  著者:: Mahlangu, Johnny N., 等
  出版事項: (2018)
• Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
  著者:: Kavakli, K, 等
  出版事項: (2015)
• BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
  著者:: Santoro, Cristina, 等
  出版事項: (2020)
• Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
  著者:: Solms, Alexander, 等
  出版事項: (2020)